Temsirolimus

Results: 62



#Item
11Who is the ideal mTOR patient ? Thomas E Hutson, DO, PharmD, FACP Professor of Medicine Director, GU Oncology Program Co-Director, GU Center of Excellence

Who is the ideal mTOR patient ? Thomas E Hutson, DO, PharmD, FACP Professor of Medicine Director, GU Oncology Program Co-Director, GU Center of Excellence

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 13:28:54
12Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 14:06:16
13What Have Sequencing Trials Taught Us? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy

What Have Sequencing Trials Taught Us? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:45
14Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen

Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 15:16:02
15Challenges for Patients on Long Term Systemic Therapy Prof. Cezary Szczylik, MD PhD Department of Oncology Military Institute of Medicine

Challenges for Patients on Long Term Systemic Therapy Prof. Cezary Szczylik, MD PhD Department of Oncology Military Institute of Medicine

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 15:25:25
16Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy

Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:46
17Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy

Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:46
18  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TORISEL safely and effectively. See full prescribing information for TORISEL.

 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TORISEL safely and effectively. See full prescribing information for TORISEL.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-06-06 11:10:23
192008  Dana Farber Harvard Cancer Center, Renal Cancer Program – Kidney Cancer Association – Survivor Conference Agenda  8:30 – Breakfast

2008 Dana Farber Harvard Cancer Center, Renal Cancer Program – Kidney Cancer Association – Survivor Conference Agenda 8:30 – Breakfast

Add to Reading List

Source URL: www.dfhcc.harvard.edu

Language: English - Date: 2011-08-31 17:02:36
20kcp winter 2009_justified_Layout 1.qxd

kcp winter 2009_justified_Layout 1.qxd

Add to Reading List

Source URL: www.dfhcc.harvard.edu

Language: English - Date: 2011-08-31 17:02:37